Patient-based drug discovery's latest news
The ANR supports our efforts in drug discovery for Myotonic Dystrophy type 1
Ksilink is happy to announce the initiation of the ANR funded project "Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)". This project is supporting...
New solutions to treat Rubinstein-Taybi
Ksilink is happy to have welcomed the team of Prof. Valérie Mezger-Lallemand from Université Didérot to initiate a collaboration with the aim to establish a new patient-based disease model to identify …
AI-powered Drug Discovery symposium
We are proud to be present with two posters (DM1 and DCM projects) during the AI powered Drug Discovery Symposium from 8-9th of November 2021 in London, at Francis Crick...
Video: Ksilink x 2CRSI
Ksilink and 2CRSI – acting together to enable next generation medicine. Collaborating since more than 5 years with 2CRSI, Ksilink is honored to be now recognized as one of...
We are proud to announce the release of our new website!
We are happy to welcome you on our new website. We will keep you informed about news and activities around patient-based drug discovery. Come and visit us on www.ksilink.com !!
Ksilink, joining academic-industry cell imaging consortium to speed patient-based drug discovery and development
Credit : Broad Institute of MIT and Harvard. Human cells imaged using Cell Painting are treated with fluorescent dyes that mark different cellular components, including the...
Virtual tour I-Stem
Ksilink is pleased to share with you this virtual tour of its partner CECS I-Stem with the following message of its founder and scientific director Marc Peschanski: “Dear...
New publication in Nature chemical biology
Dr Juyong Yoon, Project team leader at Ksilink, published a paper entitled" Permissive epigenomes endow reprogramming competence to transcriptional regulators" in Nature chemical...
Ksilink in the Strasbourg Boston Initiative 2020
Ksilink is happy to be part of the Strasbourg Boston Initiative 2020 ! At Ksilink we use every day as an opportunity to not only create new and efficient ways to work smarter but...